Concerns about inflation and valuations have U.S. advisors looking further afield than domestic stocks to find opportunities for growth while diversifying a portfolio. A somewhat common structure that has existed for decades when investing in...
Read MoreAmong the most beaten-down assets in the first month of 2022 were biotechnology stocks, with smaller members of that group enduring significant punishment. That’s the bad news. The good news is that exchange traded funds, such as the ALPS Medical...
Read MoreA trend emerging in early 2022 is growth stocks weighing on the broader market while some value issues are holding up well on a relative basis. Upon closer inspection, dividend stocks and exchange traded funds are performing significantly less...
Read MoreInterest rates are poised to rise, perhaps as soon as March. However, rates are coming off rock-bottom levels, and even as the Federal Reserve lifts borrowing costs, investors will still encounter income challenges. That is to say that this...
Read MoreIn the name of “common prosperity,” the Chinese Communist Party (CCP) unveiled a wide-ranging regulatory regime last year that sank stocks in the world’s second-largest economy, reminding investors that there’s always some form of risk to...
Read MoreEmerging markets (EM) experienced a double whammy of a strong dollar and the pandemic over the past year, but they present patient investors with a value opportunity. Some global investment firms are seeing this play out with EM still feeling the...
Read MoreExxon Mobil Corp. (NYSE: XOM) has been working to reduce its greenhouse gas emissions on multiple fronts. On Tuesday, the company announced as part of its fourth quarter earnings statement that it expects to meet its 2025 emission-reduction plans...
Read More